Showing results (241-250 of 379) with videos related to

Sort By:
Pageof 38
Nephrology (Carlton, Vic.)|November 11, 2014
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility StudyMatthew A Roberts, Helen L Pilmore, Francesco L Ierino, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression TrialsRobert A Fletcher, William G Herrington, Rajiv Agarwal, et al.
Kidney International Reports|April 29, 2021
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours HemodialysisMelissa Nataatmadja, Rathika Krishnasamy, Li Zuo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
Kidney International Supplements|January 25, 2019
Closing the gap between evidence and practice in chronic kidney diseaseMeg J Jardine, Bertram Kasiske, Dwomoa Adu, et al.
Diabetes, Obesity & Metabolism|September 21, 2020
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysisChao Li, Zien Zhou, Brendon L Neuen, et al.
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
Renal Failure|December 25, 2014
Clinical characteristics of IgA nephropathy associated with low complement 4 levelsBin Zhu, Cai-Feng Zhu, Yi Lin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 20, 2024
Canagliflozin and iron metabolism in the CREDENCE trialAkihiko Koshino, Hiddo J L Heerspink, Niels Jongs, et al.
Pageof 38